Serum interleukin 6 as a prognostic factor in patients with prostate cancer

Jun Nakashima, Masaaki Tachibana, Yutaka Horiguchi, Mototsugu Oya, Takashi Ohigashi, Hirotaka Asakura, Masaru Murai

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

The present study was undertaken to evaluate the prognostic significance of the serum levels of interleukin 6 (IL-6) in patients with prostate cancer. Serum IL-6 levels were measured in 74 patients with prostate cancer. The tumor was stage B in 23 patients, stage C in 14 patients, and stage D in 37 patients. Prognostic significance of tumor histology, performance status (PS), bone metastasis, serum prostate-specific antigen (PSA) level, serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase level, serum IL-6 levels, and hemoglobin on disease-specific survival was assessed using univariate and multivariate Cox's proportional hazards model analyses. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, and ALP >620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. In 51 patients with stage C and stage D prostate cancer, univariate analysis showed that EOD ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, LDH >200 IU/liter, and ALP >620 IU/liter were significantly related to survival, whereas multivariate analysis again demonstrated that EOD ≥1 and IL-6 ≥7 pg/ml were significant prognostic factors. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD.

Original languageEnglish
Pages (from-to)2702-2706
Number of pages5
JournalClinical Cancer Research
Volume6
Issue number7
Publication statusPublished - 2000 Jul

Fingerprint

Interleukin-6
Prostatic Neoplasms
Serum
Interleukin-7
Prostate-Specific Antigen
Alkaline Phosphatase
Multivariate Analysis
Survival
Bone Diseases
L-Lactate Dehydrogenase
Proportional Hazards Models
Neoplasms
Histology
Hemoglobins
Survival Rate
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000). Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clinical Cancer Research, 6(7), 2702-2706.

Serum interleukin 6 as a prognostic factor in patients with prostate cancer. / Nakashima, Jun; Tachibana, Masaaki; Horiguchi, Yutaka; Oya, Mototsugu; Ohigashi, Takashi; Asakura, Hirotaka; Murai, Masaru.

In: Clinical Cancer Research, Vol. 6, No. 7, 07.2000, p. 2702-2706.

Research output: Contribution to journalArticle

Nakashima, J, Tachibana, M, Horiguchi, Y, Oya, M, Ohigashi, T, Asakura, H & Murai, M 2000, 'Serum interleukin 6 as a prognostic factor in patients with prostate cancer', Clinical Cancer Research, vol. 6, no. 7, pp. 2702-2706.
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clinical Cancer Research. 2000 Jul;6(7):2702-2706.
Nakashima, Jun ; Tachibana, Masaaki ; Horiguchi, Yutaka ; Oya, Mototsugu ; Ohigashi, Takashi ; Asakura, Hirotaka ; Murai, Masaru. / Serum interleukin 6 as a prognostic factor in patients with prostate cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 7. pp. 2702-2706.
@article{9c0ba390c8a54e8fb1512408d99d4ad1,
title = "Serum interleukin 6 as a prognostic factor in patients with prostate cancer",
abstract = "The present study was undertaken to evaluate the prognostic significance of the serum levels of interleukin 6 (IL-6) in patients with prostate cancer. Serum IL-6 levels were measured in 74 patients with prostate cancer. The tumor was stage B in 23 patients, stage C in 14 patients, and stage D in 37 patients. Prognostic significance of tumor histology, performance status (PS), bone metastasis, serum prostate-specific antigen (PSA) level, serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase level, serum IL-6 levels, and hemoglobin on disease-specific survival was assessed using univariate and multivariate Cox's proportional hazards model analyses. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, and ALP >620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. In 51 patients with stage C and stage D prostate cancer, univariate analysis showed that EOD ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, LDH >200 IU/liter, and ALP >620 IU/liter were significantly related to survival, whereas multivariate analysis again demonstrated that EOD ≥1 and IL-6 ≥7 pg/ml were significant prognostic factors. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD.",
author = "Jun Nakashima and Masaaki Tachibana and Yutaka Horiguchi and Mototsugu Oya and Takashi Ohigashi and Hirotaka Asakura and Masaru Murai",
year = "2000",
month = "7",
language = "English",
volume = "6",
pages = "2702--2706",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Serum interleukin 6 as a prognostic factor in patients with prostate cancer

AU - Nakashima, Jun

AU - Tachibana, Masaaki

AU - Horiguchi, Yutaka

AU - Oya, Mototsugu

AU - Ohigashi, Takashi

AU - Asakura, Hirotaka

AU - Murai, Masaru

PY - 2000/7

Y1 - 2000/7

N2 - The present study was undertaken to evaluate the prognostic significance of the serum levels of interleukin 6 (IL-6) in patients with prostate cancer. Serum IL-6 levels were measured in 74 patients with prostate cancer. The tumor was stage B in 23 patients, stage C in 14 patients, and stage D in 37 patients. Prognostic significance of tumor histology, performance status (PS), bone metastasis, serum prostate-specific antigen (PSA) level, serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase level, serum IL-6 levels, and hemoglobin on disease-specific survival was assessed using univariate and multivariate Cox's proportional hazards model analyses. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, and ALP >620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. In 51 patients with stage C and stage D prostate cancer, univariate analysis showed that EOD ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, LDH >200 IU/liter, and ALP >620 IU/liter were significantly related to survival, whereas multivariate analysis again demonstrated that EOD ≥1 and IL-6 ≥7 pg/ml were significant prognostic factors. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD.

AB - The present study was undertaken to evaluate the prognostic significance of the serum levels of interleukin 6 (IL-6) in patients with prostate cancer. Serum IL-6 levels were measured in 74 patients with prostate cancer. The tumor was stage B in 23 patients, stage C in 14 patients, and stage D in 37 patients. Prognostic significance of tumor histology, performance status (PS), bone metastasis, serum prostate-specific antigen (PSA) level, serum alkaline phosphatase (ALP) level, serum lactate dehydrogenase level, serum IL-6 levels, and hemoglobin on disease-specific survival was assessed using univariate and multivariate Cox's proportional hazards model analyses. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, and ALP >620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. In 51 patients with stage C and stage D prostate cancer, univariate analysis showed that EOD ≥1, IL-6 ≥7 pg/ml, PS ≥1, PSA >100 ng/ml, LDH >200 IU/liter, and ALP >620 IU/liter were significantly related to survival, whereas multivariate analysis again demonstrated that EOD ≥1 and IL-6 ≥7 pg/ml were significant prognostic factors. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD.

UR - http://www.scopus.com/inward/record.url?scp=0033911711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033911711&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 2702

EP - 2706

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -